person · Reporting owner

ZOLLARS WILLIAM D

Disclosed activity across 4 companies

Tapewire entity: 15354
SEC CIK: 0001085324

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	Director	September 13, 2019	September 17, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date September 13, 2019 · Filed September 17, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	13,500	Reported balance After 2019-09-13 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-09-13 · Sale · Disposed 308 · Balance 13,500 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2019. F2: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2019.

F2: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CERNER Corp

Report date June 07, 2022 · Filed June 09, 2022

Section 16 reporting ended · disclosed 2022-06-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Revocable Trust	0	Reported balance After 2022-06-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-06-07 · Other · Disposed 26,588 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-06-08 transaction · row 2 1 source row Row 2 · 2022-06-08 · Disposition to issuer · Disposed 3,680 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the Merger Agreement, pursuant to which Merger Subsidiary merged into Cerner, effective on June 8, 2022 (the "Effective Time"), with Cerner becoming a wholly owned indirect subsidiary of Oracle. At the Effective Time, each issued and outstanding share of Cerner common stock was cancelled and converted into the right to receive $95.00 per share in cash, without interest thereon and subject to any required tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer.

F2: This Form 4 reports securities disposed of pursuant to the Merger Agreement, pursuant to which Merger Subsidiary merged into Cerner, effective on June 8, 2022 (the "Effective Time"), with Cerner becoming a wholly owned indirect subsidiary of Oracle. At the Effective Time, each issued and outstanding share of Cerner common stock was cancelled and converted into the right to receive $95.00 per share in cash, without interest thereon and subject to any required tax withholding.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	0	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 13,500 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-12-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 9,787 · Balance 0 F3: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

Prologis, Inc.

Report date May 04, 2023 · Filed May 08, 2023

Section 16 reporting ended · disclosed 2023-05-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,720	Reported balance After 2023-05-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-05-04 · Exercise / conversion · Acquired 3,232 · Balance 23,720 F1: Represents director fees that the reporting person has elected to defer into phantom shares under the NQDC Plan. These phantom shares are vested upon issuance and accrue DEUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU in accordance with the deferral election made by the reporting person, or upon termination of service. Balance in column 9 includes phantom shares and DEUs.
Deferred Stock Units and Dividend Equivalent Units-NQDCSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2023-05-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-05-04 · Exercise / conversion · Disposed 3,232.5659 · Balance 0 F1: Represents director fees that the reporting person has elected to defer into phantom shares under the NQDC Plan. These phantom shares are vested upon issuance and accrue DEUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU in accordance with the deferral election made by the reporting person, or upon termination of service. Balance in column 9 includes phantom shares and DEUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents director fees that the reporting person has elected to defer into phantom shares under the NQDC Plan. These phantom shares are vested upon issuance and accrue DEUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU in accordance with the deferral election made by the reporting person, or upon termination of service. Balance in column 9 includes phantom shares and DEUs.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 30, 2019 Filed Jun 3, 2019 16:15 UTC	CERNER Corp CERN · Entity 126375	GrantCommon Stock	3,556	$0.00	$0.00	Disclosure SEC source: 0001209191-19-033892 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 21, 2020 or the calendar day immediately preceding the date of the Cerner Corporation 2020 annual meeting of shareholders. F2 · balance_after: Includes 3,556 shares of restricted common stock. Read SEC document
May 06, 2019 Filed May 7, 2019 12:24 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionDeferred Stock Units and Dividend Equivalent Units-NQDC · Derivative	3,939.7781	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-027925 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720.7442 Underlying: Common Stock · 3,939.7781 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (May 4, 2016). Shares were released on May 6, 2019. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · price: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (May 4, 2016). Shares were released on May 6, 2019. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · derivative.exercise_date: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (May 4, 2016). Shares were released on May 6, 2019. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · derivative.expiration_date: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (May 4, 2016). Shares were released on May 6, 2019. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. Read SEC document
May 06, 2019 Filed May 7, 2019 12:24 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	3,939	$0.00	$0.00	Disclosure SEC source: 0001209191-19-027925 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (May 4, 2016). Shares were released on May 6, 2019. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. Read SEC document
May 01, 2019 Filed May 3, 2019 14:50 UTC	Prologis, Inc. PLD · Entity 2877	GrantDeferred Stock Units-NQDC · Derivative	2,448	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-027260 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,660.5223 Underlying: Common Stock · 2,448 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units (DSUs) granted May 1, 2019 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 1, 2022. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · price: Deferred Stock Units (DSUs) granted May 1, 2019 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 1, 2022. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Deferred Stock Units (DSUs) granted May 1, 2019 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 1, 2022. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Deferred Stock Units (DSUs) granted May 1, 2019 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 1, 2022. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. Read SEC document
March 29, 2019 Filed Apr 2, 2019 14:36 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	5.7145	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-022252 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781.4907 Underlying: Common Stock · 5.7145 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
March 29, 2019 Filed Apr 2, 2019 14:36 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	74.6776	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-022252 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,212.5223 Underlying: Common Stock · 74.6776 shares Expires not disclosed F1 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document
March 13, 2019 Filed Mar 15, 2019 17:11 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	272	$168.43	$45,812.50	Disclosure SEC source: 0001225208-19-005374 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019. Read SEC document
February 28, 2019 Filed Mar 4, 2019 18:39 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	272	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004410 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,772 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
January 02, 2019 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionDividend Equivalent Units · Derivative	218.7762	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · derivative · entry 6 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775.7762 Underlying: Common Stock · 218.7762 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. F2 · derivative.expiration_date: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2019 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionPhantom Stock · Derivative	557	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · derivative · entry 5 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994.5524 Underlying: Common Stock · 557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. F1 · derivative.expiration_date: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2019 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	218	$0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · nonDerivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2019 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	557	$0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
December 31, 2018 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	12.58	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · derivative · entry 4 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,551.5524 Underlying: Common Stock · 12.58 shares Expires not disclosed F4 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
December 31, 2018 Filed Jan 3, 2019 19:20 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	82.1987	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-001430 · doc4.xml · derivative · entry 3 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,137.8447 Underlying: Common Stock · 82.1987 shares Expires not disclosed F3 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:49 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerPhantom Stock Units · Derivative	9,787	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-18-008667 · doc1.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 9,787 shares Expires not disclosed F3 · security: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.exercise_price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · kind: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.exercise_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.expiration_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:49 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	13,500	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008667 · doc1.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantPhantom Stock Units · Derivative	9,787	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-18-008705 · doc1.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,787 Underlying: Common Stock $0.01 Par Value · 9,787 shares Expires not disclosed F3 · security: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.exercise_price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · kind: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.exercise_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F3 · derivative.expiration_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $0.01 Par Value	13,500	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008705 · doc1.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 19, 2018 Filed Dec 21, 2018 16:45 UTC	Prologis, Inc. PLD · Entity 2877	GiftCommon Stock	1,610	$0.00	$0.00	Disclosure SEC source: 0001209191-18-063935 · doc4.xml · nonDerivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,270 F1 · kind: Shares donated as a gift to a charitable organization. Read SEC document
December 19, 2018 Filed Dec 21, 2018 16:45 UTC	Prologis, Inc. PLD · Entity 2877	SaleCommon Stock	1,610	$61.53	$99,063.30	Disclosure SEC source: 0001209191-18-063935 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,880 Read SEC document
December 14, 2018 Filed Dec 17, 2018 18:12 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	201	$210.84	$42,378.84	Disclosure SEC source: 0001225208-18-016748 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
November 30, 2018 Filed Dec 4, 2018 18:28 UTC	Cigna Holding Co CI · Entity 161580	GrantCommon Stock, $.25 Par Value	201	$0.00	$0.00	Disclosure SEC source: 0001225208-18-016224 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,701 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:02 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	10.8204	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-053524 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,538.9724 Underlying: Common Stock · 10.8204 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:02 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	70.7002	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-053524 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,055.646 Underlying: Common Stock · 70.7002 shares Expires not disclosed F1 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document
September 14, 2018 Filed Sep 18, 2018 17:09 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	238	$193.70	$46,100.60	Disclosure SEC source: 0001225208-18-013537 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
August 31, 2018 Filed Sep 5, 2018 17:50 UTC	Cigna Holding Co CI · Entity 161580	GrantCommon Stock, $.25 Par Value	238	$0.00	$0.00	Disclosure SEC source: 0001225208-18-013186 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,738 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
July 23, 2018 Filed Jul 25, 2018 17:19 UTC	Prologis, Inc. PLD · Entity 2877	SaleCommon Stock	8,020	$62.45	$500,849.00	Disclosure SEC source: 0001209191-18-043923 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,490 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.44 to $62.47. The reporting person undertakes to provide to Prologis, Inc., any security holder of Prologis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price. Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:30 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	11.0854	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-041377 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,528.152 Underlying: Common Stock · 11.0854 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:30 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	72.4313	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-041377 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,984.9458 Underlying: Common Stock · 72.4313 shares Expires not disclosed F1 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document
June 15, 2018 Filed Jun 18, 2018 17:24 UTC	Prologis, Inc. PLD · Entity 2877	SaleCommon Stock	4,750	$64.06	$304,285.00	Disclosure SEC source: 0001209191-18-038371 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,510 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.06 to $64.065. The reporting person undertakes to provide to Prologis, Inc., any security holder of Prologis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price. Read SEC document
June 14, 2018 Filed Jun 18, 2018 17:02 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	265	$176.93	$46,886.45	Disclosure SEC source: 0001225208-18-010745 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
May 31, 2018 Filed Jun 4, 2018 17:28 UTC	Cigna Holding Co CI · Entity 161580	GrantCommon Stock, $.25 Par Value	265	$0.00	$0.00	Disclosure SEC source: 0001225208-18-010125 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,765 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
May 21, 2018 Filed May 22, 2018 16:06 UTC	CERNER Corp CERN · Entity 126375	SaleCommon Stock	3,900	$60.80	$237,120.00	Disclosure SEC source: 0001209191-18-032287 · doc4.xml · nonDerivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,972 F2 · balance_after: Includes 4,100 shares of restricted common stock. Read SEC document
May 18, 2018 Filed May 22, 2018 16:06 UTC	CERNER Corp CERN · Entity 126375	GrantCommon Stock	4,100	$0.00	$0.00	Disclosure SEC source: 0001209191-18-032287 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,872 F1 · shares: These shares represent an award of restricted common stock that will vest on the earlier of May 29, 2019 or the calendar day immediately preceding the date of Cerner's 2019 annual meeting of shareholders. F2 · balance_after: Includes 4,100 shares of restricted common stock. Read SEC document
May 02, 2018 Filed May 4, 2018 13:36 UTC	Prologis, Inc. PLD · Entity 2877	GrantDeferred Stock Units-NQDC · Derivative	2,934	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-028007 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,912.5145 Underlying: Common Stock · 2,934 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units (DSUs) granted May 2, 2018 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 2, 2021. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · price: Deferred Stock Units (DSUs) granted May 2, 2018 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 2, 2021. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Deferred Stock Units (DSUs) granted May 2, 2018 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 2, 2021. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Deferred Stock Units (DSUs) granted May 2, 2018 which vest 100% on the earlier of the first anniversary of the grant date, or the first annual meeting of the stockholders of Prologis that occurs after the grant date, and generally, are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan until May 2, 2021. DSUs earn dividend equivalent units (DEUs) when dividends are paid with respect to Prologis common stock and have no exercisable or expiration date. DSUs and accrued DEUs are convertible into Prologis common stock on a 1-for-1 basis. Balance in column 9 includes DSUs and DEUs. Read SEC document
April 30, 2018 Filed Apr 30, 2018 20:13 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionDeferred Stock Units and Dividend Equivalent Units-NQDC · Derivative	4,035.4268	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-026934 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,978.5145 Underlying: Common Stock · 4,035.4268 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (April 29, 2015). Shares were released on April 30, 2018. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · price: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (April 29, 2015). Shares were released on April 30, 2018. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · derivative.exercise_date: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (April 29, 2015). Shares were released on April 30, 2018. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. F1 · derivative.expiration_date: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (April 29, 2015). Shares were released on April 30, 2018. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. Read SEC document
April 30, 2018 Filed Apr 30, 2018 20:13 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	4,035	$0.00	$0.00	Disclosure SEC source: 0001209191-18-026934 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Conversion of Deferred Stock Units (DSUs) and Dividend Equivalent Units (DEUs) that were deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). Original grant terms provided for release of shares on third anniversary of the grant date (April 29, 2015). Shares were released on April 30, 2018. DSUs and DEUs convert into Prologis common stock upon vesting on a 1-for-1 basis, and have no exercise price or expiration date. Read SEC document
March 29, 2018 Filed Apr 3, 2018 17:04 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	11.473	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-023132 · doc4.xml · derivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517.0666 Underlying: Common Stock · 11.473 shares Expires not disclosed F2 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F2 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
March 29, 2018 Filed Apr 3, 2018 17:04 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	83.2945	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-023132 · doc4.xml · derivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,013.9413 Underlying: Common Stock · 83.2945 shares Expires not disclosed F1 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F1 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document
March 14, 2018 Filed Mar 16, 2018 16:28 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	229	$165.46	$37,889.70	Disclosure SEC source: 0001225208-18-006303 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $165.4473 to $165.47 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018. Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:25 UTC	Cigna Holding Co CI · Entity 161580	GrantCommon Stock, $.25 Par Value	229	$0.00	$0.00	Disclosure SEC source: 0001225208-18-005163 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,729 F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's preliminary proxy statement filed with the SEC on March 2, 2018. Read SEC document
February 08, 2018 Filed Feb 12, 2018 16:21 UTC	CERNER Corp CERN · Entity 126375	SaleCommon Stock	4,100	$62.16	$254,856.00	Disclosure SEC source: 0001209191-18-009188 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,772 F1 · balance_after: Includes 3,900 shares of restricted common stock. Read SEC document
February 07, 2018 Filed Feb 8, 2018 19:25 UTC	Prologis, Inc. PLD · Entity 2877	SaleCommon Stock	4,020	$60.48	$243,129.60	Disclosure SEC source: 0001209191-18-008584 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,225 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.46 to $60.50. The reporting person undertakes to provide to Prologis, Inc., any security holder of Prologis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price. Read SEC document
January 10, 2018 Filed Jan 12, 2018 17:16 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	212	$205.68	$43,604.16	Disclosure SEC source: 0001225208-18-000980 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2017. Read SEC document
January 02, 2018 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionDividend Equivalent Units · Derivative	195.7968	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · derivative · entry 6 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505.5936 Underlying: Common Stock · 195.7968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. F2 · derivative.expiration_date: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2018 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionPhantom Stock · Derivative	557	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · derivative · entry 5 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,701.3904 Underlying: Common Stock · 557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. F1 · derivative.expiration_date: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2018 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	195	$0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · nonDerivative · entry 2 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Conversion of Dividend Equivalent Units (DEUs) earned on deferred phantom stock. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
January 02, 2018 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	Exercise / conversionCommon Stock	557	$0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · nonDerivative · entry 1 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Conversion of deferred phantom stock that the reporting person earned for previous service on the ProLogis board of trustees. Settlement is in Prologis common stock on a 1-for-1 basis. Read SEC document
December 29, 2017 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units · Derivative	15.2994	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · derivative · entry 4 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,258.3904 Underlying: Common Stock · 15.2994 shares Expires not disclosed F4 · derivative.exercise_price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · price: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · derivative.exercise_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. F4 · derivative.expiration_date: Represents DEUs earned on phantom shares associated with previous service on the board of ProLogis, our merger partner, and assumed by us in June 2011. DEUs accrue on outstanding phantom shares at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs vest upon issuance and the receipt of such DEUs is deferred in accordance with the deferral election made by the reporting person applicable to the underlying phantom shares. Phantom shares and DEUs are paid in the form of Prologis common stock at the rate of one common share per phantom share or DEU. Balance in column 9 includes phantom shares and DEUs. Read SEC document
December 29, 2017 Filed Jan 3, 2018 18:19 UTC	Prologis, Inc. PLD · Entity 2877	GrantDividend Equivalent Units - NQDC · Derivative	74.049	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-001262 · doc4.xml · derivative · entry 3 ZOLLARS WILLIAM D · CIK 0001085324 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,930.6468 Underlying: Common Stock · 74.049 shares Expires not disclosed F3 · derivative.exercise_price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · price: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · derivative.exercise_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. F3 · derivative.expiration_date: Represents Dividend Equivalent Units (DEUs) earned on Deferred Stock Units (DSUs) associated with current service on our board that are deferred under the Prologis, Inc. Nonqualified Deferred Compensation Plan (the NQDC Plan). DEUs accrue on outstanding DSUs at the Prologis common stock dividend rate at the time dividends are paid on Prologis common stock. DEUs and the underlying DSUs vest 100% on the earlier of the first anniversary of the grant date or the first annual meeting of the stockholders of Prologis after the grant date (generally in May each year). The receipt of such DEUs is deferred along with the underlying DSUs. DSUs and DEUs are paid in the form of Prologis common stock at the rate of one common share per DSU or DEU. Balance in column 9 includes DSUs and DEUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.